Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02147873 · ClinicalTrials.gov registry record · Phase 2
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2 study, sponsored by TetraLogic Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
NCT02147873: Clinical Trial Phase 2 study, sponsored by TetraLogic Pharmaceuticals.
NCT02147873 is a Phase 2 study that was terminated before completion, run by TetraLogic Pharmaceuticals. The registered enrollment target is 118 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02147873, a Phase 2 study, was terminated before completion, sponsored by TetraLogic Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
Study Summary
This is a randomized double blind placebo controlled study of azacitidine with or without birinapant in subjects with higher risk Myelodysplastic syndrome, secondary MDS or myelomonocytic leukemia (CMMoL) who are naïve, to azacitidine therapy. Pre-clinical and mechanistic studies support that azacitidine may modulate pathways that enable birinapant-mediated anti-tumor activity.
Interventions
- DRUG Placebo
- DRUG Azacitidine
- DRUG birinapant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2014-06 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02147873
The ClinicalTrials.gov registry entry for NCT02147873 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TetraLogic Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02147873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02147873 about?
NCT02147873 is a clinical study titled "Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL". This is a randomized double blind placebo controlled study of azacitidine with or without birinapant in subjects with higher risk Myelodysplastic syndrome, secondary MDS or myelomonocytic leukemia (CMMoL) who are naïve, to azacitidine therapy. Pre-clinical and mechanistic studies support that azacit...
What is the current status of trial NCT02147873?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2014-06. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02147873?
The interventions under investigation include: Placebo (DRUG), Azacitidine (DRUG), birinapant (DRUG).
Who is sponsoring clinical trial NCT02147873?
This trial is sponsored by TetraLogic Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.